Invasive fungal infection: Difference between revisions
From IDWiki
(→) |
(→: added citation) |
||
| Line 9: | Line 9: | ||
== Epidemiology == |
== Epidemiology == |
||
| − | * Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection |
+ | * Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection [[CiteRef::cornely2007po]] |
[[Category:Infectious syndromes]] |
[[Category:Infectious syndromes]] |
||
Revision as of 16:41, 22 September 2019
Organisms
- Aspergillus species
- Mucormycosis
- Cryptococcus?
- Penicillium
- Others...
Epidemiology
- Among patients on posaconazole for a hematologic malignancy or bone marrow transplant, there is an approximately 2% rate of breakthrough infection 1
References
- ^ Oliver A. Cornely, Johan Maertens, Drew J. Winston, John Perfect, Andrew J. Ullmann, Thomas J. Walsh, David Helfgott, Jerzy Holowiecki, Dick Stockelberg, Yeow-Tee Goh, Mario Petrini, Cathy Hardalo, Ramachandran Suresh, David Angulo-Gonzalez. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. New England Journal of Medicine. 2007;356(4):348-359. doi:10.1056/nejmoa061094.
